BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25120359)

  • 1. The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient.
    Song Y; Huang Z; Song Y; Tian Q; Liu X; She Z; Jiao J; Lu E; Deng Y
    Int J Nanomedicine; 2014; 9():3611-21. PubMed ID: 25120359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
    Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
    J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.
    Jiang SP; He SN; Li YL; Feng DL; Lu XY; Du YZ; Yu HY; Hu FQ; Yuan H
    Int J Nanomedicine; 2013; 8():3141-50. PubMed ID: 23990722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
    Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q
    J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradient.
    Yang Y; Ma Y; Wang S
    Eur J Pharm Biopharm; 2012 Feb; 80(2):332-9. PubMed ID: 22041601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.
    Huang Y; Yang T; Zhang W; Lu Y; Ye P; Yang G; Li B; Qi S; Liu Y; He X; Lee RJ; Xu C; Xiang G
    Int J Nanomedicine; 2014; 9():4581-95. PubMed ID: 25302024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property.
    Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C
    AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multifunctional Lipid Incorporating Active Targeting and Dual-Control Release Capabilities for Precision Drug Delivery.
    Liu C; Ewert KK; Yao W; Wang N; Li Y; Safinya CR; Qiao W
    ACS Appl Mater Interfaces; 2020 Jan; 12(1):70-85. PubMed ID: 31774266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and pharmacokinetics of a novel pirarubicin liposome powder.
    Cong W; Liu Q; Chen X; Gao R; Lu J; Wang Y; Luo G
    Drug Dev Ind Pharm; 2010 Oct; 36(10):1186-94. PubMed ID: 20515395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
    Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
    Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.
    Kousani S; Karimi M; Teymouri M; Navashenaq JG; Darban SA; Jaafari MR
    Biotechnol Prog; 2021 Nov; 37(6):e3202. PubMed ID: 34405574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.
    Chiang YT; Lo CL
    Biomaterials; 2014 Jul; 35(20):5414-5424. PubMed ID: 24709521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting.
    Zhang H; Xiao Y; Cui S; Zhou Y; Zeng K; Yan M; Zhao C
    J Nanosci Nanotechnol; 2015 Jun; 15(6):4058-69. PubMed ID: 26369013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.